Storia in 2 fonti

Eli Lilly says Verve’s gene editor lowers cholesterol levels in early study

Eli Lilly said Monday that a high dose of its gene-editing therapy reduced cholesterol levels by 62% in participants in a clinical trial.

Raccontata da

statnews.com

morningstar.com

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

statnews.comStai leggendo9 h fa

Eli Lilly says Verve’s gene editor lowers cholesterol levels in early study

Eli Lilly said Monday that a high dose of its gene-editing therapy reduced cholesterol levels by 62% in participants in a clinical trial.

originale

morningstar.com9 h fa

A single dose of Lilly's PCSK9 base editor, VERVE-102, reduced PCSK9 by up to 88% and LDL-C by up to 62%,…

A single dose of Lilly's VERVE-102 base editor reduced PCSK9 by up to 88% and LDL-C by up to 62% in Phase 1b, with effects sustained for 18 months across 35 patients with familial hypercholesterolemia or premature CAD. For health tech and biopharma investors, this signals a credible shift from chronic lipid-lowering therapy (statins, PCSK9 inhibitors) to a one-time genomic intervention, with Phase 2 enrollment starting before end of 2026.

Eli Lilly says Verve’s gene editor lowers cholesterol levels in early study

Confronto fonti

Eli Lilly says Verve’s gene editor lowers cholesterol levels in early study

A single dose of Lilly's PCSK9 base editor, VERVE-102, reduced PCSK9 by up to 88% and LDL-C by up to 62%,…

Timeline cronologica

Eli Lilly says Verve’s gene editor lowers cholesterol levels in early study

A single dose of Lilly's PCSK9 base editor, VERVE-102, reduced PCSK9 by up to 88% and LDL-C by up to 62%, with durable effects supporting…